Skip to main content
Erschienen in: World Journal of Urology 2/2019

20.07.2018 | Review

Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms—outcomes from a network meta-analysis

verfasst von: Zhongyu Jian, Yuntian Chen, Qinyu Liu, Banghua Liao, Tongxin Yang, Hong Li, Kunjie Wang

Erschienen in: World Journal of Urology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To systematically evaluate the different efficacy among generally used drugs for stent-related symptoms (SRS) with the method of network meta-analysis.

Methods

A systematic search was performed in the US National Library of Medicine’s life science database (Medline), Embase, the Cochrane Central Register of Controlled Trials, and the Cochrane Database for Systematic Reviews before December 2017. Analysis was performed under multivariate random-effects network model and effects of drugs were ranked with surface under the cumulative ranking (SUCRA) probabilities.

Results

19 trials with 2036 patients investigating 4 different intervention including tamsulosin (Tam), alfuzosin (Alfu), solifenacin (Soli) and combination of Tam and Solif were finally included in our analysis. Tam plus Soli had the highest SUCRA on all aspects of ureteral stent symptom questionnaire: urinary symptoms (86.2%), body pain (85.0%), general health (80.5%), work performance (72.0%) and sexual performance (84.4%). Except for pain relief, Soli showed higher SUCRA than Tam or Alfu in rest respects. Tam and Alfu showed similar SUCRA on urinary symptoms (53.0 vs 48.7%) and body pain relief (61.9 vs 62.9%).

Conclusions

Tam plus Soli might be the most effective intervention for SRSs. As for monotherapy, Soli showed advantages in most respects except for pain relief compared to Tam or Alfu. Tam and Alfu showed similar efficacy on urinary symptoms and body pain relief.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Zimskind PD, Fetter TR, Wilkerson JL (1967) Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol 97:840–844CrossRefPubMed Zimskind PD, Fetter TR, Wilkerson JL (1967) Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol 97:840–844CrossRefPubMed
2.
Zurück zum Zitat Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG (2002) Characterization of urinary symptoms in patients with ureteral stents. Urology 59:511–516CrossRefPubMed Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG (2002) Characterization of urinary symptoms in patients with ureteral stents. Urology 59:511–516CrossRefPubMed
3.
Zurück zum Zitat Joshi HB, Stainthorpe A, Keeley FX Jr, MacDonagh R, Timoney AG (2001) Indwelling ureteral stents: evaluation of quality of life to aid outcome analysis. J Endourol 15:151–154CrossRefPubMed Joshi HB, Stainthorpe A, Keeley FX Jr, MacDonagh R, Timoney AG (2001) Indwelling ureteral stents: evaluation of quality of life to aid outcome analysis. J Endourol 15:151–154CrossRefPubMed
4.
Zurück zum Zitat Betschart P, Zumstein V, Piller A, Schmid HP, Abt D (2017) Prevention and treatment of symptoms associated with indwelling ureteral stents: a systematic review. Int J Urol 24:250–259CrossRefPubMed Betschart P, Zumstein V, Piller A, Schmid HP, Abt D (2017) Prevention and treatment of symptoms associated with indwelling ureteral stents: a systematic review. Int J Urol 24:250–259CrossRefPubMed
5.
Zurück zum Zitat Wang J, Zhang X, Zhang T, Mu J, Bai B, Lei Y (2017) The role of solifenacin, as monotherapy or combination with tamsulosin in ureteral stent-related symptoms: a systematic review and meta-analysis. World J Urol 35:1669–1680CrossRefPubMed Wang J, Zhang X, Zhang T, Mu J, Bai B, Lei Y (2017) The role of solifenacin, as monotherapy or combination with tamsulosin in ureteral stent-related symptoms: a systematic review and meta-analysis. World J Urol 35:1669–1680CrossRefPubMed
6.
Zurück zum Zitat Mills EJTK, Ioannidis JP (2013) Demystifying trial networks and network meta-analysis. BMJ 346:f2914CrossRef Mills EJTK, Ioannidis JP (2013) Demystifying trial networks and network meta-analysis. BMJ 346:f2914CrossRef
7.
Zurück zum Zitat Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700CrossRefPubMedPubMedCentral Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ (2006) A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol 59:342–353CrossRefPubMed Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ (2006) A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol 59:342–353CrossRefPubMed
9.
Zurück zum Zitat Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:163–171CrossRef Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:163–171CrossRef
10.
Zurück zum Zitat Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis IM (2006) Is there a role for alpha 1-blockers in treating double-J stent-related symptoms? Urology 67:35–39CrossRefPubMed Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis IM (2006) Is there a role for alpha 1-blockers in treating double-J stent-related symptoms? Urology 67:35–39CrossRefPubMed
11.
Zurück zum Zitat Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D’Armiento M (2008) Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol 22:651–656CrossRefPubMed Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D’Armiento M (2008) Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol 22:651–656CrossRefPubMed
12.
Zurück zum Zitat Beddingfield R, Pedro RN, Hinck B, Kreidberg C, Feia K, Monga M (2009) Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J Urol 181:170–176CrossRefPubMed Beddingfield R, Pedro RN, Hinck B, Kreidberg C, Feia K, Monga M (2009) Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J Urol 181:170–176CrossRefPubMed
13.
Zurück zum Zitat Park SC, Jung SW, Lee JW, Rim JS (2009) The effects of tolterodine extended release and alfuzosin for the treatment of double-J stent-related symptoms. J Endourol 23:1913–1917CrossRefPubMed Park SC, Jung SW, Lee JW, Rim JS (2009) The effects of tolterodine extended release and alfuzosin for the treatment of double-J stent-related symptoms. J Endourol 23:1913–1917CrossRefPubMed
14.
Zurück zum Zitat Wang CJ, Huang SW, Chang CH (2009) Effects of specific α-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol Res 37:147–152CrossRefPubMed Wang CJ, Huang SW, Chang CH (2009) Effects of specific α-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol Res 37:147–152CrossRefPubMed
15.
Zurück zum Zitat Nazim SM, Ather MH (2012) Alpha-blockers impact stent-related symptoms: a randomized, double-blind, placebo-controlled trial. J Endourol 26:1237–1241CrossRefPubMed Nazim SM, Ather MH (2012) Alpha-blockers impact stent-related symptoms: a randomized, double-blind, placebo-controlled trial. J Endourol 26:1237–1241CrossRefPubMed
16.
Zurück zum Zitat Lee YJ, Huang KH, Yang HJ, Chang HC, Chen J, Yang TK (2013) Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis 41:247–252CrossRefPubMed Lee YJ, Huang KH, Yang HJ, Chang HC, Chen J, Yang TK (2013) Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis 41:247–252CrossRefPubMed
17.
Zurück zum Zitat Dellis AE, Keeley FX, Manolas V, Skolarikos AA (2014) Role of α-blockers in the treatment of stent-related symptoms: a prospective randomized control study. Urology 83:56–61CrossRefPubMed Dellis AE, Keeley FX, Manolas V, Skolarikos AA (2014) Role of α-blockers in the treatment of stent-related symptoms: a prospective randomized control study. Urology 83:56–61CrossRefPubMed
18.
Zurück zum Zitat Singh I, Tripathy S, Agrawal V (2014) Efficacy of tamsulosin hydrochloride in relieving “double-J ureteral stent-related morbidity”: a randomized placebo controlled clinical study. Int Urol Nephrol 46:2279–2283CrossRefPubMed Singh I, Tripathy S, Agrawal V (2014) Efficacy of tamsulosin hydrochloride in relieving “double-J ureteral stent-related morbidity”: a randomized placebo controlled clinical study. Int Urol Nephrol 46:2279–2283CrossRefPubMed
19.
Zurück zum Zitat Park J, Yoo C, Han DH, Shin DW (2015) A critical assessment of the effects of tamsulosin and solifenacin as monotherapies and as a combination therapy for the treatment of ureteral stent-related symptoms: a 2 × 2 factorial randomized trial. World J Urol 33:1833–1840CrossRefPubMed Park J, Yoo C, Han DH, Shin DW (2015) A critical assessment of the effects of tamsulosin and solifenacin as monotherapies and as a combination therapy for the treatment of ureteral stent-related symptoms: a 2 × 2 factorial randomized trial. World J Urol 33:1833–1840CrossRefPubMed
20.
Zurück zum Zitat Abdelaal AM, Al-Adl AM, Abdelbaki SA, Al Azab MM, Al Gamal KA (2016) Efficacy and safety of tamsulosin oral-controlled absorption system, solifenacin, and combined therapy for the management of ureteric stent-related symptoms. Arab J Urol 14:115–122CrossRefPubMedPubMedCentral Abdelaal AM, Al-Adl AM, Abdelbaki SA, Al Azab MM, Al Gamal KA (2016) Efficacy and safety of tamsulosin oral-controlled absorption system, solifenacin, and combined therapy for the management of ureteric stent-related symptoms. Arab J Urol 14:115–122CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat EL-Nahas AR, Tharwat M, Elsaadany M, Mosbah A, Gaballah MA (2016) A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms. World J Urol 34:963–968CrossRefPubMed EL-Nahas AR, Tharwat M, Elsaadany M, Mosbah A, Gaballah MA (2016) A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms. World J Urol 34:963–968CrossRefPubMed
22.
Zurück zum Zitat Hekal IA (2016) Drug treatment of bothersome lower urinary tract symptoms after ureteric JJ-stent insertion: a contemporary, comparative, prospective, randomised placebo-controlled study, single-centre experience. Arab J Urol 14:262–268CrossRefPubMedPubMedCentral Hekal IA (2016) Drug treatment of bothersome lower urinary tract symptoms after ureteric JJ-stent insertion: a contemporary, comparative, prospective, randomised placebo-controlled study, single-centre experience. Arab J Urol 14:262–268CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Liu Q, Liao B, Zhang R et al (2016) Combination therapy only shows short-term superiority over monotherapy on ureteral stent-related symptoms–outcome from a randomized controlled trial. BMC Urol 16:66CrossRefPubMedPubMedCentral Liu Q, Liao B, Zhang R et al (2016) Combination therapy only shows short-term superiority over monotherapy on ureteral stent-related symptoms–outcome from a randomized controlled trial. BMC Urol 16:66CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Maldonado-Avila M, Garduño-Arteaga L, Jungfermann-Guzman R et al (2016) Efficacy of tamsulosin, oxybutynin, and their combination in the control of double-j stent-related lower urinary tract symptoms. Int Braz J Urol 42:487–493CrossRefPubMedPubMedCentral Maldonado-Avila M, Garduño-Arteaga L, Jungfermann-Guzman R et al (2016) Efficacy of tamsulosin, oxybutynin, and their combination in the control of double-j stent-related lower urinary tract symptoms. Int Braz J Urol 42:487–493CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Zhang L, Li J, Pan M, Han W, Liu S, Xiao Y (2016) Doxazosin oral intake therapy to relieve stent-related urinary symptoms and pain: a prospective, randomized, controlled study. Int Braz J Urol 42:727–733CrossRefPubMedPubMedCentral Zhang L, Li J, Pan M, Han W, Liu S, Xiao Y (2016) Doxazosin oral intake therapy to relieve stent-related urinary symptoms and pain: a prospective, randomized, controlled study. Int Braz J Urol 42:727–733CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Abdelhamid MH, Zayed AS, Ghoneima WE et al (2017) Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms. World J Urol 35:1261–1268CrossRefPubMed Abdelhamid MH, Zayed AS, Ghoneima WE et al (2017) Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms. World J Urol 35:1261–1268CrossRefPubMed
27.
Zurück zum Zitat Dellis AE, Papatsoris AG, Keeley FX Jr et al (2017) Tamsulosin, solifenacin, and their combination for the treatment of stent-related symptoms: a randomized controlled study. J Endourol 31:100–109CrossRefPubMed Dellis AE, Papatsoris AG, Keeley FX Jr et al (2017) Tamsulosin, solifenacin, and their combination for the treatment of stent-related symptoms: a randomized controlled study. J Endourol 31:100–109CrossRefPubMed
28.
Zurück zum Zitat Ragab M, Soliman MG, Tawfik A et al (2017) The role of pregabalin in relieving ureteral stent-related symptoms: a randomized controlled clinical trial. Int Urol Nephrol 49:961–966CrossRefPubMed Ragab M, Soliman MG, Tawfik A et al (2017) The role of pregabalin in relieving ureteral stent-related symptoms: a randomized controlled clinical trial. Int Urol Nephrol 49:961–966CrossRefPubMed
29.
Zurück zum Zitat Tanidir Y, Mangir N, Sahan A, Ulukaya M (2016) Turkish version of the ureteral stent symptoms questionnaire: linguistic and psychometric validation. World J Urol 35:1149–1154CrossRefPubMed Tanidir Y, Mangir N, Sahan A, Ulukaya M (2016) Turkish version of the ureteral stent symptoms questionnaire: linguistic and psychometric validation. World J Urol 35:1149–1154CrossRefPubMed
30.
Zurück zum Zitat White I (2009) Multivariate random-effects meta-analysis. Stata J 9:40–56CrossRef White I (2009) Multivariate random-effects meta-analysis. Stata J 9:40–56CrossRef
31.
Zurück zum Zitat Lange D, Bidnur S, Hoag N, Chew BH (2015) Ureteral stent-associated complications—where we are and where we are going. Nat Rev Urol 12:17–25CrossRefPubMed Lange D, Bidnur S, Hoag N, Chew BH (2015) Ureteral stent-associated complications—where we are and where we are going. Nat Rev Urol 12:17–25CrossRefPubMed
32.
Zurück zum Zitat Yamaguchi O (2013) Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action. Int J Urol 20:28–39CrossRefPubMed Yamaguchi O (2013) Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action. Int J Urol 20:28–39CrossRefPubMed
33.
Zurück zum Zitat Mokhtari G, Shakiba M, Ghodsi S et al (2011) Effect of terazosin on lower urinary tract symptoms and pain due to double-J stent: a double-blind placebo-controlled randomized clinical trial. Urol Int 87:19–22CrossRefPubMed Mokhtari G, Shakiba M, Ghodsi S et al (2011) Effect of terazosin on lower urinary tract symptoms and pain due to double-J stent: a double-blind placebo-controlled randomized clinical trial. Urol Int 87:19–22CrossRefPubMed
34.
Zurück zum Zitat Tehranchi A, Rezaei Y, Khalkhali H, Rezaei M (2013) Effects of terazosin and tolterodine on ureteral stent related symptoms: a double-blind placebo-controlled randomized clinical trial. Int Braz J Urol 39:832–840CrossRefPubMed Tehranchi A, Rezaei Y, Khalkhali H, Rezaei M (2013) Effects of terazosin and tolterodine on ureteral stent related symptoms: a double-blind placebo-controlled randomized clinical trial. Int Braz J Urol 39:832–840CrossRefPubMed
35.
Zurück zum Zitat Kuyumcuoglu U, Eryildirim B, Tuncer M, Tarhan F, Ozgül A (2012) Effectiveness of medical treatment in overcoming the ureteral double-J stent related symptoms. Can Urol Assoc J 6:E234–E237CrossRefPubMed Kuyumcuoglu U, Eryildirim B, Tuncer M, Tarhan F, Ozgül A (2012) Effectiveness of medical treatment in overcoming the ureteral double-J stent related symptoms. Can Urol Assoc J 6:E234–E237CrossRefPubMed
Metadaten
Titel
Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms—outcomes from a network meta-analysis
verfasst von
Zhongyu Jian
Yuntian Chen
Qinyu Liu
Banghua Liao
Tongxin Yang
Hong Li
Kunjie Wang
Publikationsdatum
20.07.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 2/2019
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-018-2404-6

Weitere Artikel der Ausgabe 2/2019

World Journal of Urology 2/2019 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.